金复康口服液联合培美曲塞治疗非小细胞肺癌的临床研究

目的研究金复康口服液联合注射用培美曲塞二钠治疗非小细胞肺癌的临床疗效。方法选取2016年1月—2018年1月南京市胸科医院诊治的120例非小细胞肺癌患者作为研究对象,采用随机对照表法将患者分为对照组和治疗组,每组各60例。对照组静脉滴注注射用培美曲塞二钠500 mg/m~2,静脉输注10 min以上;治疗组患者在对照组治疗的基础上口服金复康口服液,30 mL/次,3次/d。21 d为1个疗程,两组均持续治疗2个疗程。观察两组患者的临床疗效,同时比较两组治疗前后的生活质量(QOL)评分、KPS评分、无进展生存期(PFS)、总生存期(OS)和免疫功能指标水平。结果治疗后,对照组和治疗组的客观缓解率和疾病控制率比较差异无统计学意义。治疗后,两组患者QOL和KPS评分均显著升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组QOL评分和KPS评分显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组患者PFS和OS显著长于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者CD3+、CD4+、NK和CD4+/CD8+水平显著升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗后治疗组免疫功能指标水平显著高于对照组,两组比较差异具有统计学意义(P0.05)。结论金复康口服液联合注射用培美曲塞二钠治疗非小细胞肺癌具有较好的临床疗效,能够改善患者生活质量,提高免疫功能,且安全性较高,具有一定临床推广应用价值。

Clinical study on Jinfukang Oral Liquid combined with pemetrexed in treatment of non-small cell lung cancer

Objective To study the clinical efficacy of Jinfukang Oral Liquid combined with Pemetrexed Disodium for injection in treatment of non-small cell lung cancer. Methods Patients (120 cases) with non-small cell lung cancer in Nanjing Chest Hospital from January 2016 to January 2018 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Pemetrexed Disodium for injection, 500 mg/m², and intravenous infusion for more than 10 min. Patients in the treatment group were po administered with Jinfukang Oral Liquid on the basis of control group, 30 mL/time, three times daily. A course of treatment had 21 d, and patients in two groups were treated for 2 courses. After treatment, the clinical efficacies were evaluated, and the QOL score, KPS, PFS, OS, and the immune function indexes in two groups before and after treatment were compared. Results After treatment, there was no significant difference in objective remission rate and disease control rate between the control group and the treatment group. After treatment, the QOL and KPS scores in two groups were significantly increased, and there were differences in the same group (P<0.05). After treatment, the QOL and KPS scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). After treatment, PFS and OS in the treatment group were significantly longer than those in the control group, with significant difference between two groups (P<0.05). After treatment, the CD3⁺, CD4⁺, NK, and CD4⁺/CD8⁺ levels in two groups were significantly increased, and there were differences in the same group (P<0.05). And the immune function indexes in the treatment group after treatment were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Jinfukang Oral Liquid combined with Pemetrexed Disodium for injection in treatment of non-small cell lung cancer has a good clinical effect, can improve the quality of life of patients, and improve immune function, and has a high safety, which has a certain clinical application value.